NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Relay Therapeutics, Inc. RLAY
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$15.4M
▲ 53.4% vs FY2024
EPS · FY25
$-1.61
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-41.1%
Net margin · FY25
-1800.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 15.4M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 1801 cents on every revenue dollar this year.
Per share
USD -1.61
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-41.1%
Return on equity, FY2025
ROE
Operating margin-1971.6%
Net margin-1800.6%
Return on assets-37.0%
Each USD of equity lost 41 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−28.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+123.2%
−28.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.17B
Shares outstanding, FY2025
Change, 5 years+93.4%
Change, 10 years—
The share count grew 93% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 621.3M
total assets, end of FY2025
Total assetsUSD 621.3M
EquityUSD 567.1M
CashUSD 84.0M
Current ratio22.61×
Equity funds 91% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.1
·
Operating income $B
−0.3
−0.4
−0.4
−0.3
−0.4
−0.1
−0.1
EBITDA $B
−0.3
−0.4
−0.4
−0.3
−0.4
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.3
−0.3
−0.3
−0.3
−0.4
−0.1
−0.1
EPS, diluted $
−1.61
−2.36
−2.79
−2.59
−3.82
−5.40
−21.82
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−41.1
−44.2
−40.2
−31.4
−43.8
−18.0
·
Shares out B
0.17
0.17
0.13
0.12
0.11
0.09
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed